Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Legend Biotech Corporation (NASDAQ:LEGN), with a market capitalization of $6.74 billion, has emerged as a prominent player in the biotechnology sector, primarily due to the success of its flagship ...

Discover the top genomics startups revolutionizing genome sequencing technologies to enhance disease prevention and treatment ...

A Winnipeg-based biotechnology company says it's open to any financial help it can get from Ottawa as the U.S. continues to ...

Researchers at Durham University have achieved a major advancement in understanding how proteins bind metals inside cells, a process ...

Gameto Announces FDA IND Clearance for Fertilo, the First iPSC-Based Therapy to Enter U.S. Phase 3 Clinical Trials ...

From a margin perspective, Danaher's operations should eventually improve once top-line growth rebounds. With that operating leverage-related margin expansion, we expect Danaher's adjusted EPS to grow ...

Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...

A new ML-guided platform can design thousands of new enzymes, predict how they will behave in the real world, and test their ...

Enhanc3D Genomics launched a suite of 3D multi-omics solutions to accelerate drug development during a presentation at last ...